Pharmaceutical

Risk adjusted net present value: What is the current valuation of Atai Life Sciences’s RL-007?

RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Diabetic Neuropathic Pain.

Jul 2, 2024 - 04:00
RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Diabetic Neuropathic Pain.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Influ...

Next Article

Risk adjusted net present value: What is the current valuation of Vertex Pharmac...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients

STAT+: ‘A tug of war’: Europe braces for new legislatio...

Apr 25, 2023

Bluejay touts positive data for chronic hepatitis D treatment

Bluejay touts positive data for chronic hepatitis D tre...

Jun 6, 2024

STAT+: Europe issues maximum antitrust fine of $475 million to Illumina over Grail deal

STAT+: Europe issues maximum antitrust fine of $475 mil...

Jul 12, 2023